Research ArticleOriginal Article
Open Access

Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital

Ali A. Ruwayni, Eman E. AlObary and Khalid M. Alyahya
Saudi Medical Journal January 2024, 45 (1) 34-39; DOI: https://doi.org/10.15537/smj.2024.45.1.20230236

Article Figures & Data

Tables

  • Table 1

    - Demographic general health characteristics of the respondents (n=92).

    Characteristicsn (%)
    Gender
    Male40 (43.5)
    Female52 (56.5)
    Age
    ≤303 (3.3)
    31-5020 (21.7)
    51-7045 (48.9)
    >7024 (26.1)
    Comorbidities
    No16 (17.4)
    Yes76 (82.6)
    Type of patient
    Naive84 (91.3)
    Experience8 (8.7)

    Values are presented as numbers and precentages (%).

    • Table 2

      - Distribution of the clinical characteristics related kidney and liver status.

      Characteristicsn (%)
      Stages of liver fibrosis
      F 036 (39.1)
      F I10 (10.9)
      F II10 (10.9)
      F III7 (7.6)
      F IV29 (31.5)
      Kidney stage
      G 130 (32.3)
      G 228 (30.1)
      G 3a9 (9.7)
      G 3b3 (3.2)
      G 43 (3.2)
      G 519 (20.4)
      On hemodialysis
      Yes17 (18.5)
      No75 (81.5)
      HCV genotype
      Not carried out13 (14.1)
      GT I3 (3.3)
      GT I (a)6 (6.5)
      GT I (b)11 (12.0)
      GT 1 & 45 (5.4)
      GT 25 (5.4)
      GT 2 & 31 (1.1)
      GT 33 (3.3)
      GT 445 (48.9)
      Child-Pugh class
      A78 (84.8)
      B4 (4.3)
      C10 (10.9)
      Duration of treatment
      8 weeks23 (25.0)
      12 weeks69 (75.0)

      Values are presented as numbers and precentages (%). G: grade, F: stage of fibrosis, GT: genotype

      • Table 3

        - Effectiveness and adherence of glecaprevir/pibrentasvir among Saudi population at a single tertiary hospital.

        Outcomesn (%)95% CI
        Overall SVR1291 (98.9)94-99.8
        Virologic non-response1 (1.1)0.2-5.9
        Virologic failure
        Yes0 (2.2)-
        No0 (94.6)-
        Missing data92 (3.3)-
        Appropriate duration of treatment (8 vs 12 weeks)
        Yes23 (25.0)16.6-35.1
        No69 (75.0)65.2-83
        SVR12 achievement according to duration of treatment
        8 weeks23 (100)85-100
        12 weeks68 (98.5)92.2-99.7

        Values are presented as numbers and precentages and 95% confidence interval (CI). SVR12: sustained virologic response

        • Table 4

          - Distribution of physicians who prescribed appropriate and inappropriate duration, either 8 or 12 months, according to FDA recommendation.

          Physicians’ gradeAppropriate duration according to FDA recommendation (8 vs 12 weeks)Chi-square testP-value
           YesNo5.20.022
          Registrars7 (15.0)40 (85.0)
          Consultants16 (36.0)29 (64.0)

          Values are presented as numbers and precentages (%). FDA: US Food and Drug Administration

          • Table 5

            - Safety of glecaprevir/pibrentasvir among Saudi population at a single tertiary hospital.

            Outcomesn (%)95% CI
            Elevation in ALT
            Grade 083 (91.2)82.2-95.4
            Grade I6 (6.6)2.4-13.7
            Grade II2 (2.2)0.3-7.6
            No data1 (1.1)-
            Elevation in bilirubin
            Grade 082 (89.1)80.9-94.7
            Grade I4 (4.3)1.2-10.8
            Grade II2 (2.2)0.3-7.6
            Grade III3 (3.3)0.7-9.2
            No data1 (1.1)-
            Elevation in AST
            Grade 084 (91.3)83.6-96.2
            Grade I5 (5.4)1.8-12.2
            Grade II2 (2.2)0.3-7.6
            Grade III1 (1.1)-
            Skin itching
            Grade I1 (1.1)-

            Values are presented as numbers and precentages and and 95% confidence interval (CI). ALT: alanine aminotransferase, AST: aspartate transferase

            Back to top

            In this issue

            Print
            Download PDF
            Email Article
            Citation Tools
            Bookmark this article

            Jump to section

            Keywords